Browse > Article

Effects of Resveratrol on the Pharmacokinetics of Nifedipine in Rats  

Choi, Byung-Chul (Health Insurance Review and Assessment Service)
Choi, Jun-Shik (College of Pharmacy, Chosun University)
Publication Information
YAKHAK HOEJI / v.54, no.4, 2010 , pp. 252-257 More about this Journal
Abstract
The aim of this study was to investigate the effect of resveratrol on the pharmacokinetics of nifedipine in rats. The pharmacokinetic parameters of nifedipine were measured after the oral administration of nifenipine (6 mg/kg) in the presence or absence of resveratrol (0.5, 2.5 and 10 mg/kg, respectively). The effect of resveratrol on the P-glycoprotein (Pgp), CYP 3A4 activity was also evaluated. Resveratrol inhibited CYP3A4 enzyme activity in a concentration-dependent manner with 50% inhibition concentration ($IC_{50}$) of 0.94 ${\mu}M$. In addition, resveratrol significantly enhanced the cellular accumulation of rhodamine 123 in MCF-7/ADR cells overexpressing P-gp. Compared to the control groups, the presence of 2.5 mg/kg and 10 mg/kg of resveratrol significantly (p<0.05, p<0.01) increased the area under the plasma concentrationtime curve (AUC) of nifedipine by 49~75%, and the peak concentration ($C_{max}$) of nifedipine by 48~66%. The absolute bioavailability (AB%) of nifedipine was significantly (p<0.05) increased by 22.9-34.8% compared to the control (19.8%). The terminal half-life ($T_{1/2}$) of nifedipine was significantly (p<0.05) increased compared to the control. While there was no significant change in the time to reach the peak plasma concentration ($T_{max}$) of nifedipine in the presence of resveratrol. It might be suggested that resveratrol altered disposition of nifedipine by inhibition of both the CYP3A and P-glycoprotein efflux pump in the small intestine of rats. In conclusion, the presence of resveratrol significantly enhanced the oral bioavailability of nifedipine, suggesting that concurrent use of resveratrol or resveratrol-containing dietary supplenment with nifedipine should require close monitoring for potential drug interation.
Keywords
nifedipine; resveratrol; pharmacokinetics; CYP3A; p-glycoprotein; first-pass metabolism; rats;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Na, J. H. and Choi, J. S. : Effect of naringin on the pharmacokinetics of nifedipine in rats. J. Kor. Pharm. Sci. 35, 101 (2005).   과학기술학회마을
2 Sorkin, E. M., Clissold, S. P. and Brogden, R. N. : Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs. 30, 182 (1985).   DOI   ScienceOn
3 Jang, M., Cai, L., Udeani, G. O., et al. : Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218 (1997).   DOI
4 Guengerich, F. P. : Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 48, 2946 (1988).
5 Chan, W. K. and Delucchi, A. B. : Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci. 67, 3103 (2000).   DOI   ScienceOn
6 Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225 (1999).   DOI   ScienceOn
7 Piver, B., Berthou, F., Dreano, Y., et al. : Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol. Lett. 125, 83 (2001).   DOI   ScienceOn
8 Chang, T. K. H., Chen, J. and Yu, C. T. : In vitro inhibition of rat CYP1A1 and CYP1A2 by piceatannol, a hydroxylated metabolite of resveratrol. Drug Metab. Lett. 1, 13 (2007).   DOI   ScienceOn
9 Soleas, G. J., Diamandis, E. P. and Golberg, D. M. : Resveratrol: a molecule whose time has come? and gone? Clin. Biochem. 30, 91 (1997a).   DOI   ScienceOn
10 Frankel, E. N., Waterhouse, A. L. and Kinsella, J. E. : Inhibition of human LDL oxidation by resveratrol. Lancet. 341, 1103 (1993).
11 Soleas, G. J., Diamandis, E. P. and Golberg, D. M. : Wine as a biological fluid: history, production, and role in disease prevention. J. Clin. Lab. Anal. 11, 287 (1997b).   DOI   ScienceOn
12 Constant, J. : Alcohol, ischemic heart disease, and the French paradox. Coronary Artery. Dis. 8, 645 (1997).   DOI   ScienceOn
13 Fruehauf, J. P. and Manetta, A. : Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR1 expression. Contrib. Gynecol. Obstet. 19, 39 (1994).
14 Grundy, J. S., Kherani, R. and Foster, R. T. : Sensitive highperformance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J. Chromatogr B. Biomed. Appl. 654, 146 (1994).   DOI   ScienceOn
15 Crespi, C. L., Miller, V. P. and Penman, B. W. : Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188 (1997).   DOI   ScienceOn
16 Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine. 16, 203 (1983).   DOI   ScienceOn
17 Fauconneau, B., Waffo-Teguo, P., Huguet, F., et al. : Comparative study of radical scavenger and antioxidant properties of phenolic compounds from vitis vinifera cell cultures using in vitro tests. Life Sci. 61, 2103 (1997).
18 Han, H. K., Lee, I. K. and Choi, J. S. : Pharmacokinetic interaction between nifedipine and quercetin in rabbits. J. Kor. Pharm. Sci. 34, 283 (2004).   과학기술학회마을
19 Hong, S. P., Choi, D. H. and Choi, J. S. : Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. Cardiovascular. 26, 269 (2008).   DOI
20 Choi, J. S., Choi, B. C. and Kang, K. W. : Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Pharmazie. 64, 49 (2009).
21 Guengerich, F. P., Brian, W. R. and Iwasaki, M. : Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 3A4. J. Med. Chem. 4, 1838 (1991).
22 Lee, J. K. and Choi, J. S. : Effect of morim on the pharmacokinetics of nifedipine in rats. Yakhak Hoeji 51, 169 (2007).   과학기술학회마을
23 Chaudhary, P. M. and Robinson, I. B. : Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 66, 85 (1991).   DOI   ScienceOn
24 Van Asperen, J., Van Tellingen, O., Sparreboom, A., et al. : Enhanced oral bilavailability of diltiazem in mice treated with the p-glycoprotein blocker. Br. J. Cancer. 76, 1181 (1997).   DOI   ScienceOn
25 Biedler, J. L. and Riehm, H. : Cellular resistance to actinomycin D in Chinese hamster cells in vitro: crossresistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174 (1970).
26 Ford, J. M. : Modulators of multidrug resistance preclinical studies. Hematol. Oncol. Clin. N. Am. 9, 337 (1995).
27 Iribarne, C., Dréano, L. G., Bardou, J. F., et al. : Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 117, 13 (1997).   DOI   ScienceOn
28 Watkins, P. B., Wrighton, S. A., Schuetz, E. G., et al. : Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest. 80, 1029 (1987).   DOI
29 Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993).   DOI   ScienceOn
30 Kolars, J. C., Schmiedlin-Ren, P., Dobbins, 3rd W. O., et al. : Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102, 1186 (1992).   DOI
31 Gan, S. L., Moseley, M. A., Khosla, B., et al. : CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24, 344 (1996).
32 Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161 (1996).
33 Wacher, V. H., Silverman, J. A., Zhang, Y., et al. : Role of Pglycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998).   DOI
34 Henry, P. D. : Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am. J. Cardiol. 46, 1047 (1980).   DOI   ScienceOn
35 Nabekura, T., Kamiyama, S. and Kitagawa, S. : Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun. 327, 866 (2005).   DOI   ScienceOn
36 Walter, D. G., Gruchy, B. S., Renwick, A. G., et al. : The firstpass metabolism of nifedipine in man. Br. J. Clin. Pharmacol. 18, 951 (1984).   DOI   ScienceOn
37 Raemsch, K. and Sommer, J. C. : Pharmacokinetics and metabolism of nifedipine. Hypertension. 5, 18 (1983).
38 Bertelli, A. A. E., Giovanni, L., Stradi, R., et al. : Kinetics of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after red wine oral administration in rats. Int. J. Clin Pharmacol Res. 26, 77 (1996).